Becton, Dickinson and Company (BDX)
Automate Your Wheel Strategy on BDX
With Tiblio's Option Bot, you can configure your own wheel strategy including BDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BDX
- Rev/Share 72.3516
- Book/Share 87.5175
- PB 2.0367
- Debt/Equity 0.7634
- CurrentRatio 1.1268
- ROIC 0.0435
- MktCap 51087697750.0
- FreeCF/Share 8.9802
- PFCF 19.725
- PE 34.3186
- Debt/Assets 0.3538
- DivYield 0.0228
- ROE 0.0586
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BDX | Citigroup | Buy | Neutral | -- | $185 | May 22, 2025 |
| Downgrade | BDX | Piper Sandler | Overweight | Neutral | -- | $185 | May 2, 2025 |
| Downgrade | BDX | Raymond James | Outperform | Market Perform | -- | -- | May 2, 2025 |
| Downgrade | BDX | Goldman | Buy | Neutral | -- | $192 | May 2, 2025 |
| Downgrade | BDX | William Blair | Outperform | Market Perform | -- | -- | May 1, 2025 |
| Downgrade | BDX | BofA Securities | Buy | Neutral | -- | $190 | May 1, 2025 |
| Downgrade | BDX | Wells Fargo | Overweight | Equal Weight | -- | -- | May 1, 2025 |
| Upgrade | BDX | Citigroup | Neutral | Buy | $255 | $275 | Oct. 1, 2024 |
News
Earnings Preview: Becton Dickinson (BDX) Q3 Earnings Expected to Decline
Published: July 31, 2025 by: Zacks Investment Research
Sentiment: Negative
Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
BD Receives FDA 510(k) Clearance for Rapid Point-of-Care COVID-19 Test
Published: July 30, 2025 by: PRNewsWire
Sentiment: Neutral
New CLIA-Waived Test Delivers Digital Results to Support Timely Clinical Decision-Making FRANKLIN LAKES, N.J. , July 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD Veritor™ System for SARS-CoV-2, a digital test designed to detect COVID-19 antigens in symptomatic individuals in about 15 minutes at doctors' offices, urgent care centers, retail clinics and other convenient points of care.
Read More
Best Dividend Kings: July 2025
Published: July 22, 2025 by: Seeking Alpha
Sentiment: Positive
14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently appear undervalued with strong long-term return potential, using Dividend Yield Theory for valuation.
Read More
BD Partners With Waters to Build High-Volume Diagnostics Leader
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
BDX collaborates with Waters in a $17.5B deal to form a diagnostics powerhouse targeting $9B in revenues by 2030.
Read More
Becton Dickinson gets its spinoff deal, but the stock is still falling
Published: July 14, 2025 by: Market Watch
Sentiment: Neutral
Becton Dickinson will spin off its biosciences and diagnostic business and merge it with Waters, and plans to use at least $2 billion of the proceeds to buy back stock.
Read More
Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing
Published: July 14, 2025 by: PRNewsWire
Sentiment: Neutral
Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growth Creates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion Increases annual recurring revenue to over 70% with over 80% of revenue coming from iconic market-leading brands Anticipate approximately $345 million in annualized EBITDA synergies by 2030, including $200 million of cost synergies by year three, and $290 million of revenue synergies by year five Delivers …
Read More
Becton, Dickinson: A Dividend King Facing Challenges Offers Value
Published: June 09, 2025 by: Seeking Alpha
Sentiment: Positive
Becton, Dickinson is significantly undervalued, trading at 12.3x earnings with a 2.5% dividend yield, the highest in a decade. The company boasts a 53-year streak of dividend growth, excellent dividend safety, and a conservative payout ratio, making it a reliable Dividend King. Despite tariff headwinds, competition, and restructuring risks, BDX's innovation, acquisitions, and organic growth support long-term revenue and EPS expansion.
Read More
BD Stock Might See Short-term Decline After Warning on Tamponade Tubes
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Negative
BDX warns of safety risks tied to its esophagogastric balloon tamponade tubes after one death and two injuries, prompting updated usage instructions for clinicians.
Read More
Cancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs'
Published: May 21, 2025 by: PRNewsWire
Sentiment: Neutral
FRANKLIN LAKES, N.J. , May 21, 2025 /PRNewswire/ -- First-of-their-kind studies published in The Lancet Oncology 1 and Cancer Medicine 2 provide new data showing that cancer patients in both hospital and outpatient settings are at a substantially higher risk of developing antimicrobial resistant (AMR) infections compared to all other non-cancer patients.
Read More
BD Stock May Rise Following the Launch of FACSDiscover A8 Platform
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
BDX unveils the BD FACSDiscover A8, a next-gen cell analyzer with spectral flow cytometry and real-time imaging, enabling deeper insights into cell function and biology.
Read More
BD to Announce Financial Results for its Third Quarter of Fiscal 2025
Published: May 12, 2025 by: PRNewsWire
Sentiment: Neutral
FRANKLIN LAKES, N.J. , May 12, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m.
Read More
Buy 3 "Safer" Dividend Kings Of 25 From May's 55
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Positive
The May collection of Dividend Kings grew to 55, with Automatic Data Processing and RLI Corporation joining, despite two companies dropping off for not increasing dividends. Six top-yield Dividend Kings, including Altria and Canadian Utilities, are now fairly priced, with annual dividends from $1K investments exceeding their single-share prices. Analysts predict net gains of 14.7% to 56.86% for the top ten Dividend Kings by yield for the coming year, based on target prices. Among the 55 Dividend Kings, 16 show negative free cash flow margins, making them cash-poor and unsafe for investment.
Read More
Medical-products maker Becton Dickinson says cuts in global research funding have hurt sales
Published: May 01, 2025 by: Market Watch
Sentiment: Negative
Becton Dickinson & Co.'s stock fell more than 15% on Thursday toward its worst one-day loss in 26 years after the medical-products maker said global cuts in research funding are impacting its research instrument sales.
Read More
Becton, Dickinson and Company (BDX) Q2 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Becton, Dickinson and Company (NYSE:BDX ) Q2 2025 Results Conference Call May 1, 2025 8:00 AM ET Company Participants Greg Rodetis - Senior Vice President, Treasurer and Head of Investor Relations Tom Polen - Chairman, Chief Executive Officer and President Chris DelOrefice - Executive Vice President and Chief Financial Officer Mike Garrison - President of the Medical Mike Feld - President of the Life Sciences Rick Byrd - President of the Interventional Conference Call Participants Larry Biegelsen - Wells Fargo Robbie Marcus - JPMorgan Matt Taylor - Jefferies Travis Steed - Bank of America Patrick Wood - Morgan Stanley David …
Read More
Becton Dickinson (BDX) Reports Q2 Earnings: What Key Metrics Have to Say
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Becton Dickinson (BDX) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Cramer's Stop Trading: Becton Dickinson
Published: May 01, 2025 by: CNBC Television
Sentiment: Neutral
CNBC's Jim Cramer explains why he is keeping an eye on shares of Becton Dickinson.
Read More
Becton Dickinson (BDX) Q2 Earnings Top Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Becton Dickinson (BDX) came out with quarterly earnings of $3.35 per share, beating the Zacks Consensus Estimate of $3.28 per share. This compares to earnings of $3.17 per share a year ago.
Read More
Medical device maker Becton Dickinson cuts 2025 profit forecast on potential tariff hit
Published: May 01, 2025 by: Reuters
Sentiment: Negative
Medical device maker Becton Dickinson lowered its annual profit forecast on Thursday, in anticipation of a potential hit from U.S. President Donald Trump's tariffs, sending its shares down 5% in premarket trading.
Read More
BD Reports Second Quarter Fiscal 2025 Financial Results
Published: May 01, 2025 by: PRNewsWire
Sentiment: Neutral
Revenue of $5.3 billion increased 4.5% as reported, 6.0% currency-neutral and 0.9% organic GAAP and adjusted diluted EPS of $1.07 and $3.35, respectively Company updates full-year fiscal 2025 guidance and provides estimated tariff impact FRANKLIN LAKES, N.J., May 1, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 second quarter, which ended March 31, 2025.
Read More
MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
This earnings season so far has reflected a continued recovery in sales for companies within the Medical sector. Earnings have increased year over year, albeit at a slower pace than revenues.
Read More
Can Sustained Product Demand Drive BDX Stock Before Q2 Earnings?
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The continued solid uptake of BD's products is expected to have driven fiscal second-quarter revenues despite transitory market dynamics.
Read More
2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market
Published: April 23, 2025 by: Seeking Alpha
Sentiment: Positive
The Dividend Kings are outperforming the S&P 500 in 2025 by 8.94%. Top performers include National Fuel & Gas (+28.88%), Consolidated Edison (+28.10%), and Middlesex Water Company (+21.00%). Promising Dividend Kings identified in March showed relative outperformance, averaging -3.15% vs. -8.16% for SPY.
Read More
BD Stock Down Despite Monitoring Platform Launch to Boost Patient Care
Published: April 22, 2025 by: Zacks Investment Research
Sentiment: Negative
BDX's AI-based advanced hemodynamic monitoring platform is likely to aid clinicians to address blood flow instability and pressure in critical situations and improve patient outcomes.
Read More
BD Launches Next Generation Hemodynamic Monitoring Solution Providing Clinicians with AI-Driven Clinical Decision Support
Published: April 21, 2025 by: PRNewsWire
Sentiment: Neutral
HemoSphere Alta™ Advanced Monitoring Platform with Predictive, Smart Algorithms Helps Clinicians Proactively Address Instability in Blood Flow and Pressure in Critical Situations FRANKLIN LAKES, N.J. , April 21, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has launched a new advanced hemodynamic monitoring platform with predictive, artificial intelligence (AI) based algorithms that can help clinicians proactively address blood pressure instability and optimize blood flow to help avoid potential life-threatening situations during procedures.
Read More
BDX Stock Declines Following Class I Classification for Alaris Recall
Published: March 26, 2025 by: Zacks Investment Research
Sentiment: Negative
BD's recall of Alaris infusion pumps following software issues has been classified as the most severe recall by the FDA. A suspension of sales may hurt the top line going forward.
Read More
BDX Shares May Climb as GalaFLEX LITE Trial Hits Key Milestone
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
BD advances its clinical trial for the bioabsorbable GalaFLEX LITE scaffold, aiming to improve outcomes in breast implant revision surgeries and patient recovery.
Read More
BD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery
Published: March 20, 2025 by: PRNewsWire
Sentiment: Neutral
FRANKLIN LAKES, N.J. , March 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the first patient treated in an Investigational Device Exemption (IDE) clinical trial intended to advance BD's efforts to achieve Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the use of GalaFLEX LITE™ Scaffold in decreasing capsular contracture (CC) recurrence during breast revision surgery.
Read More
Here's Why Becton Dickinson (BDX) is a Strong Value Stock
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why Becton Dickinson (BDX) is a Strong Momentum Stock
Published: March 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Becton, Dickinson and Company (BDX) Barclays 27th Annual Global Healthcare Conference Transcript
Published: March 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Becton, Dickinson and Company (NYSE:BDX ) Barclays 27th Annual Global Healthcare Conference March 11, 2025 8:30 AM ET Company Participants Tom Polen - Chairman, Chief Executive Officer and President Chris DelOrefice - Executive Vice President and Chief Financial Officer Conference Call Participants Unidentified Analyst [Call Starts Abruptly] Everyone for joining us today. We are so pleased to have with us again this year the team from Becton, Dickinson, Tom Polen, Chairman, Chief Executive Officer and Chris DelOrefice, EVP and Chief Financial Officer.
Read More
About Becton, Dickinson and Company (BDX)
- IPO Date 1973-02-21
- Website https://www.bd.com
- Industry Medical - Instruments & Supplies
- CEO Thomas E. Polen Jr.
- Employees 70000